Print Page      Close Window     

Investors

SEC Filings

6-K
OBSEVA SA filed this Form 6-K on 03/30/2018
Entire Document
 


LOGO

 

IMPLANT2 A phase 3, double-blind, placebo-controlled study to assess the safety and efficacy of a single oral administration of nolasiban to improve pregnancy rates following IVF or ICSI in Day 3 and Day 5 Fresh Embryo Transfer cycles.